Zealand Pharma A/S

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: DK0060257814
DKK
336.00
302.6 (905.99%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

360.55 k

Shareholding (Mar 2026)

FII

0.00%

Held by 1 FIIs

DII

100.00%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

DKK 22,101 Million ()

stock-summary
P/E

3.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.86

stock-summary
Return on Equity

44.34%

stock-summary
Price to Book

1.49

Revenue and Profits:
Net Sales:
34 Million
(Quarterly Results - Mar 2026)
Net Profit:
-394 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
843.01%
0%
843.01%
6 Months
1265.85%
0%
1265.85%
1 Year
1145.83%
0%
1145.83%
2 Years
2418.74%
0%
2418.74%
3 Years
1993.46%
0%
1993.46%
4 Years
1967.69%
0%
1967.69%
5 Years
1393.37%
0%
1393.37%

Zealand Pharma A/S for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
91.98%
EBIT Growth (5y)
60.84%
EBIT to Interest (avg)
-66.89
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.11
Tax Ratio
0.39%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
3
Industry P/E
Price to Book Value
1.44
EV to EBIT
0.91
EV to EBITDA
0.90
EV to Capital Employed
137.24
EV to Sales
0.71
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
15109.81%
ROE (Latest)
44.34%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 319.75% vs -46.36% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -17.51% vs -46.68% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "34.00",
          "val2": "8.10",
          "chgp": "319.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-529.00",
          "val2": "-379.50",
          "chgp": "-39.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "8.00",
          "val2": "8.10",
          "chgp": "-1.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "8.00",
          "val2": "27.10",
          "chgp": "-70.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-394.00",
          "val2": "-335.30",
          "chgp": "-17.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15,852.90%",
          "val2": "-47,634.90%",
          "chgp": "3,178.20%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 14,596.81% vs -81.71% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 698.35% vs -53.30% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9,214.90",
          "val2": "62.70",
          "chgp": "14,596.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7,183.20",
          "val2": "-1,243.20",
          "chgp": "677.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "37.70",
          "val2": "40.90",
          "chgp": "-7.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-131.30",
          "val2": "38.60",
          "chgp": "-440.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6,455.00",
          "val2": "-1,078.80",
          "chgp": "698.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "776.60%",
          "val2": "-20,243.30%",
          "chgp": "2,101.99%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoYstock-summary

Mar'26
Mar'25
Change(%)
Net Sales
34.00
8.10
319.75%
Operating Profit (PBDIT) excl Other Income
-529.00
-379.50
-39.39%
Interest
8.00
8.10
-1.23%
Exceptional Items
8.00
27.10
-70.48%
Consolidate Net Profit
-394.00
-335.30
-17.51%
Operating Profit Margin (Excl OI)
-15,852.90%
-47,634.90%
3,178.20%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2026 is 319.75% vs -46.36% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -17.51% vs -46.68% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
9,214.90
62.70
14,596.81%
Operating Profit (PBDIT) excl Other Income
7,183.20
-1,243.20
677.80%
Interest
37.70
40.90
-7.82%
Exceptional Items
-131.30
38.60
-440.16%
Consolidate Net Profit
6,455.00
-1,078.80
698.35%
Operating Profit Margin (Excl OI)
776.60%
-20,243.30%
2,101.99%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 14,596.81% vs -81.71% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 698.35% vs -53.30% in Dec 2024

stock-summaryCompany CV
About Zealand Pharma A/S stock-summary
stock-summary
Zealand Pharma A/S
Pharmaceuticals & Biotechnology
Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.
Company Coordinates stock-summary
Company Details
Sydmarken 11 , SOEBORG None : 2860
Registrar Details